Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Cergutuzumab amunaleukin
Synonyms
Therapy Description

Cergutuzumab amunaleukin (RG7813) is a bispecific antibody that binds carcinoembyronic antigen (CEA) and CD3, potentially resulting in enhanced T-cell response to CEA-expresssing tumor cells (European Journal of Cancer, Volume 51, Supplement 1, March 2015, Page S13, PMID: 28405498).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cergutuzumab amunaleukin RO6895882|RG7813|CEA TCB|RG-7813 CD3 Antibody 99 Cergutuzumab amunaleukin (RG7813) is a bispecific antibody that binds carcinoembyronic antigen (CEA) and CD3, potentially resulting in enhanced T-cell response to CEA-expresssing tumor cells (European Journal of Cancer, Volume 51, Supplement 1, March 2015, Page S13, PMID: 28405498).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02004106 Phase I Cergutuzumab amunaleukin A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors Completed USA | NLD | GBR | FRA | FIN | ESP | DNK | CHE 0
NCT02350673 Phase I Cergutuzumab amunaleukin Atezolizumab A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors Completed USA | NLD | ESP | DNK | CHE | CAN 0


Additional content available in CKB BOOST